Cerity Partners
REPL icon

Cerity Partners’s Replimune Group REPL Stock Holding History

Cerity Partners’s Portfolio REPL Stock Details REPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.85M Buy
167,504
+149,082
+809% +$912K ﹤0.01% 1636
2026
Q1 		$141K Buy
+18,422
New +$141K ﹤0.01% 2967

Other funds holding REPL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCI
Ridgeback Capital Investments Miami Beach, Florida $80.9M AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Cerity Partners's REPL Position: Q2 2026 in Review

Cerity Partners increased its Replimune Group (REPL) stake by 809% in Q2 2026, buying an estimated $912K and bringing the position to 167,504 shares worth $1.85M. The position accounts for ﹤0.01% of the portfolio, ranked #1636.

Cerity Partners first reported a position in REPL in Q1 2026 and has held it in 2 quarters since. 199 funds tracked by Wall St. Rank hold REPL as of Q2 2026.

  • Cerity Partners held 167,504 shares of Replimune Group worth $1.85M as of Q2 2026.
  • Cerity Partners bought 149,082 Replimune Group shares in Q2 2026, an estimated $912K.
  • Replimune Group made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #1636 holding.
  • Cerity Partners first reported a position in Replimune Group in Q1 2026 and has held it in 2 quarters since.
  • 199 funds tracked by Wall St. Rank held Replimune Group as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.